T5000 to rapidly and accurately detect and characterize pathogens at
the International Conference on Antimicrobial Agents and Chemotherapy
(ICAAC) and the Annual Infectious Disease Society of America
-- Provided development plan for the next-generation instrument platform,
which will build upon Ibis' current technology and be tailored for use
in a clinical diagnostic setting
Regulus Therapeutics (microRNA Joint Venture)
-- Published research in Molecular and Cellular Biology demonstrating that
the microRNA, miR-21, plays a key role in the regulation of certain
cancer cells, including an aggressive form of brain cancer
-- Published research in Cancer Cell showing that the microRNA, miR-296,
is involved in promoting the formation of new blood vessels in cancer
-- Added Stelios Papadopoulos to its Board of Directors and appointed
Garry Menzel as Executive Vice President
-- Granted patents that significantly expand the scope of Isis' "Crooke"
patent estate. U.S. Patent No. 7,432,250 and U.S. Patent No. 7,432,249
add broad claims that cover RNA-based product compositions and methods
At 8:30 a.m. Eastern Time today, November 10, Isis will conduct a live webcast conference call to discuss this earnings release and related activities. Interested parties may access the webcast at http://www.isispharm.com or listen to the call by dialing 877-795-3604. A webcast replay will be available for a limited time at the same address.
About Isis Pharmaceuticals, Inc.
Isis is exploiting its expertise in RNA to discover and develop novel
drugs for its product pipeline and for its partners. The Company has
successfully commercialized the world's first antisense drug and has 1
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved